{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:36:38Z","timestamp":1794980198217,"version":"4.9.1"},"reference-count":263,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Action de Recherche Concert\u00e9e","award":["ARC23\/28-129"],"award-info":[{"award-number":["ARC23\/28-129"]}]},{"name":"Action de Recherche Concert\u00e9e","award":["ARC23\/28-129"],"award-info":[{"award-number":["ARC23\/28-129"]}]},{"name":"Action de Recherche Concert\u00e9e","award":["ARC23\/28-129"],"award-info":[{"award-number":["ARC23\/28-129"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neoadjuvant chemotherapy (NAC) is a cornerstone in the treatment of early-stage high-risk breast cancers (BC), particularly in triple-negative, HER2-positive, and selected hormone receptor-positive subtypes. However, its effectiveness is frequently hindered by intrinsic or acquired resistance, resulting in a significant residual cancer burden (RCB) in more than half of patients. Despite extensive genomic profiling, reliable predictive biomarkers for treatment response remain limited, impeding the development of personalized therapeutic strategies. Emerging evidence highlights tumor metabolic reprogramming as a key non-genetic mechanism contributing to NAC resistance. In this review, we critically examine current advances in metabolic imaging and metabolomics as tools to predict NAC response in BC. We also discuss the role of the tumor microenvironment (TME), including hypoxia and acidosis, in shaping metabolic plasticity and fostering treatment resistance. Furthermore, we explore novel therapeutic strategies targeting metabolic pathways, ranging from enzyme inhibition to dietary interventions, and the use of advanced preclinical models. Together, these insights offer a metabolic framework for overcoming NAC resistance and advancing precision oncology in early-stage BC.<\/jats:p>","DOI":"10.1186\/s13046-025-03500-w","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T04:01:16Z","timestamp":1754884876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Resistance to neoadjuvant chemotherapy in breast cancers: a metabolic perspective"],"prefix":"10.1186","volume":"44","author":[{"given":"Manon","family":"Desgres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melis","family":"Poyraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buse","family":"Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois P.","family":"Duhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"van Marcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Corbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"3","key":"3500_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3500_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamaoncol.2023.4837","volume":"10","author":"JD Benitez Fuentes","year":"2024","unstructured":"Benitez Fuentes JD, Morgan E, de Luna Aguilar A, Mafra A, Shah R, Giusti F, et al. Global stage distribution of breast cancer at diagnosis: A systematic review and Meta-Analysis. JAMA Oncol. 2024;10(1):71\u20138.","journal-title":"JAMA Oncol"},{"issue":"2","key":"3500_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andre F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159\u201382.","journal-title":"Ann Oncol"},{"issue":"1","key":"3500_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"G Collaborative","year":"2018","unstructured":"Early Breast Cancer Trialists\u2019, Collaborative G. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27\u201339.","journal-title":"Lancet Oncol"},{"issue":"9938","key":"3500_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"3","key":"3500_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","volume":"170","author":"W Haque","year":"2018","unstructured":"Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170(3):559\u201367.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3500_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149\u201360.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3500_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso F, O\u2019Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)\/HER2(-) breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(2):442\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"3500_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi S, Salgado R, Curigliano G, Romero Diaz RI, Delaloge S, Rojas Garcia CI, et al. Neoadjuvant nivolumab and chemotherapy in early Estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(2):433\u201341.","journal-title":"Nat Med"},{"issue":"1","key":"3500_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, et al. Neoadjuvant trastuzumab, Pertuzumab, and chemotherapy versus trastuzumab emtansine plus Pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115\u201326.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3500_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/annonc\/mdx773","volume":"29","author":"SM Swain","year":"2018","unstructured":"Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29(3):646\u201353.","journal-title":"Ann Oncol"},{"key":"3500_CR12","doi-asserted-by":"crossref","unstructured":"Derouane F, van Marcke C, Berliere M, Gerday A, Fellah L, Leconte I et al. Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine. Cancers (Basel). 2022;14(16):3876","DOI":"10.3390\/cancers14163876"},{"issue":"3","key":"3500_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.celrep.2013.12.041","volume":"6","author":"V Almendro","year":"2014","unstructured":"Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014;6(3):514\u201327.","journal-title":"Cell Rep"},{"issue":"2","key":"3500_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","volume":"4","author":"JM Balko","year":"2014","unstructured":"Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232\u201345.","journal-title":"Cancer Discov"},{"issue":"4","key":"3500_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance evolution in Triple-Negative breast cancer delineated by Single-Cell sequencing. Cell. 2018;173(4):879\u201393. e13.","journal-title":"Cell"},{"issue":"7","key":"3500_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nm.3886","volume":"21","author":"LR Yates","year":"2015","unstructured":"Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21(7):751\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"3500_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13073-024-01286-8","volume":"16","author":"G Yin","year":"2024","unstructured":"Yin G, Liu L, Yu T, Yu L, Feng M, Zhou C, et al. Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy. Genome Med. 2024;16(1):11.","journal-title":"Genome Med"},{"issue":"2","key":"3500_CR18","doi-asserted-by":"publisher","first-page":"100086","DOI":"10.1016\/j.esmoop.2021.100086","volume":"6","author":"E Ortolan","year":"2021","unstructured":"Ortolan E, Appierto V, Silvestri M, Miceli R, Veneroni S, Folli S, et al. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy. ESMO Open. 2021;6(2):100086.","journal-title":"ESMO Open"},{"issue":"6","key":"3500_CR19","doi-asserted-by":"publisher","first-page":"102164","DOI":"10.1016\/j.xcrm.2025.102164","volume":"6","author":"ES Seo","year":"2025","unstructured":"Seo ES, Park S, Cho EY, Lee JE, Jung HH, Hyeon J, et al. Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype. Cell Rep Med. 2025;6(6):102164.","journal-title":"Cell Rep Med"},{"key":"3500_CR20","doi-asserted-by":"publisher","first-page":"100949","DOI":"10.1016\/j.neo.2023.100949","volume":"46","author":"M Winter","year":"2023","unstructured":"Winter M, Nait Eldjoudi A, Guette C, Hondermarck H, Bourette RP, Fovez Q, et al. Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy. Neoplasia. 2023;46:100949.","journal-title":"Neoplasia"},{"key":"3500_CR21","doi-asserted-by":"crossref","unstructured":"Goldman A, Khiste S, Freinkman E, Dhawan A, Majumder B, Mondal J et al. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. Sci Signal. 2019;12(595):eaas8779.","DOI":"10.1126\/scisignal.aas8779"},{"issue":"7679","key":"3500_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 Inhibition. Nature. 2017;551(7679):247\u201350.","journal-title":"Nature"},{"key":"3500_CR23","doi-asserted-by":"crossref","unstructured":"Derouane F, Ambroise J, van Marcke C, Van Bockstal M, Berliere M, Galant C et al. Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial-mesenchymal transition and tumor-infiltrating lymphocytes. Mol Oncol. 2025.","DOI":"10.1002\/1878-0261.13813"},{"issue":"1","key":"3500_CR24","doi-asserted-by":"publisher","first-page":"14863","DOI":"10.1038\/s41598-019-51335-1","volume":"9","author":"MV Fournier","year":"2019","unstructured":"Fournier MV, Goodwin EC, Chen J, Obenauer JC, Tannenbaum SH, Brufsky AM. A predictor of pathological complete response to neoadjuvant chemotherapy stratifies triple negative breast cancer patients with high risk of recurrence. Sci Rep. 2019;9(1):14863.","journal-title":"Sci Rep"},{"issue":"1","key":"3500_CR25","doi-asserted-by":"publisher","first-page":"21411","DOI":"10.1038\/s41598-023-48657-6","volume":"13","author":"AJA Freitas","year":"2023","unstructured":"Freitas AJA, Nunes CR, Mano MS, Causin RL, Santana IVV, de Oliveira MA, et al. Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial. Sci Rep. 2023;13(1):21411.","journal-title":"Sci Rep"},{"key":"3500_CR26","doi-asserted-by":"publisher","first-page":"704655","DOI":"10.3389\/fimmu.2021.704655","volume":"12","author":"C Fu","year":"2021","unstructured":"Fu C, Liu Y, Han X, Pan Y, Wang HQ, Wang H, et al. An Immune-Associated genomic signature effectively predicts pathologic complete response to neoadjuvant Paclitaxel and Anthracycline-Based chemotherapy in breast cancer. Front Immunol. 2021;12:704655.","journal-title":"Front Immunol"},{"issue":"18","key":"3500_CR27","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jama.2011.593","volume":"305","author":"C Hatzis","year":"2011","unstructured":"Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305(18):1873\u201381.","journal-title":"JAMA"},{"issue":"26","key":"3500_CR28","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1200\/JCO.2006.05.6861","volume":"24","author":"KR Hess","year":"2006","unstructured":"Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with Paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;24(26):4236\u201344.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3500_CR29","first-page":"3611","volume":"11","author":"M Oshi","year":"2021","unstructured":"Oshi M, Gandhi S, Angarita FA, Kim TH, Tokumaru Y, Yan L, et al. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive\/HER2-negative breast cancer. Am J Cancer Res. 2021;11(7):3611\u201327.","journal-title":"Am J Cancer Res"},{"issue":"24","key":"3500_CR30","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1158\/1078-0432.CCR-16-0471","volume":"22","author":"DG Stover","year":"2016","unstructured":"Stover DG, Coloff JL, Barry WT, Brugge JS, Winer EP, Selfors LM. The role of proliferation in determining response to neoadjuvant chemotherapy in breast cancer: A gene Expression-Based Meta-Analysis. Clin Cancer Res. 2016;22(24):6039\u201350.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3500_CR31","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1200\/JCO.2000.18.8.1689","volume":"18","author":"M Schelling","year":"2000","unstructured":"Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18(8):1689\u201395.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3500_CR32","first-page":"1144","volume":"46","author":"J Dose Schwarz","year":"2005","unstructured":"Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005;46(7):1144\u201350.","journal-title":"J Nucl Med"},{"issue":"8","key":"3500_CR33","doi-asserted-by":"publisher","first-page":"e2914","DOI":"10.1097\/MD.0000000000002914","volume":"95","author":"J Luo","year":"2016","unstructured":"Luo J, Zhou Z, Yang Z, Chen X, Cheng J, Shao Z, et al. The value of 18F-FDG PET\/CT imaging combined with pretherapeutic Ki67 for early prediction of pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer. Med (Baltim). 2016;95(8):e2914.","journal-title":"Med (Baltim)"},{"issue":"6","key":"3500_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12149-018-1253-0","volume":"32","author":"D Molina-Garcia","year":"2018","unstructured":"Molina-Garcia D, Garcia-Vicente AM, Perez-Beteta J, Amo-Salas M, Martinez-Gonzalez A, Tello-Galan MJ, et al. Intratumoral heterogeneity in (18)F-FDG PET\/CT by textural analysis in breast cancer as a predictive and prognostic subrogate. Ann Nucl Med. 2018;32(6):379\u201388.","journal-title":"Ann Nucl Med"},{"issue":"5","key":"3500_CR35","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s00259-020-04684-3","volume":"47","author":"P Li","year":"2020","unstructured":"Li P, Wang X, Xu C, Liu C, Zheng C, Fulham MJ, et al. (18)F-FDG PET\/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(5):1116\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"3500_CR36","doi-asserted-by":"publisher","first-page":"e1646","DOI":"10.1093\/oncolo\/oyae185","volume":"29","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li Y, Chen B, Zhang Y, Xing W, Guo B, et al. 18F-FDG PET\/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis. Oncologist. 2024;29(12):e1646\u201355.","journal-title":"Oncologist"},{"key":"3500_CR37","doi-asserted-by":"publisher","first-page":"849626","DOI":"10.3389\/fonc.2022.849626","volume":"12","author":"L Yang","year":"2022","unstructured":"Yang L, Chang J, He X, Peng M, Zhang Y, Wu T, et al. PET\/CT-based radiomics analysis May help to predict neoadjuvant chemotherapy outcomes in breast cancer. Front Oncol. 2022;12:849626.","journal-title":"Front Oncol"},{"issue":"3","key":"3500_CR38","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-017-3849-3","volume":"45","author":"N Cho","year":"2018","unstructured":"Cho N, Im SA, Cheon GJ, Park IA, Lee KH, Kim TY, et al. Integrated (18)F-FDG PET\/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45(3):328\u201339.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"3500_CR39","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1007\/s13277-014-2495-7","volume":"35","author":"AM Garcia Vicente","year":"2014","unstructured":"Garcia Vicente AM, Cruz Mora MA, Leon Martin AA, Munoz Sanchez Mdel M, Relea Calatayud F, Van Gomez Lopez O, et al. Glycolytic activity with 18F-FDG PET\/CT predicts final neoadjuvant chemotherapy response in breast cancer. Tumour Biol. 2014;35(11):11613\u201320.","journal-title":"Tumour Biol"},{"issue":"5","key":"3500_CR40","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.breast.2012.12.020","volume":"22","author":"BB Koolen","year":"2013","unstructured":"Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, et al. FDG PET\/CT during neoadjuvant chemotherapy May predict response in ER-positive\/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast. 2013;22(5):691\u20137.","journal-title":"Breast"},{"issue":"13","key":"3500_CR41","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1007\/s00259-023-06394-y","volume":"50","author":"RD Seban","year":"2023","unstructured":"Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, et al. [18F]FDG PET\/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab. Eur J Nucl Med Mol Imaging. 2023;50(13):4024\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10437","key":"3500_CR42","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","volume":"403","author":"JM Perez-Garcia","year":"2024","unstructured":"Perez-Garcia JM, Cortes J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024;403(10437):1649\u201359.","journal-title":"Lancet"},{"issue":"8","key":"3500_CR43","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2967\/jnumed.115.166322","volume":"57","author":"HW Lee","year":"2016","unstructured":"Lee HW, Lee HM, Choi SE, Yoo H, Ahn SG, Lee MK, et al. The prognostic impact of early change in 18F-FDG PET SUV after neoadjuvant chemotherapy in patients with locally advanced breast cancer. J Nucl Med. 2016;57(8):1183\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"3500_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11307-018-1181-3","volume":"21","author":"K Paydary","year":"2019","unstructured":"Paydary K, Seraj SM, Zadeh MZ, Emamzadehfard S, Shamchi SP, Gholami S, et al. The evolving role of FDG-PET\/CT in the diagnosis, staging, and treatment of breast cancer. Mol Imaging Biol. 2019;21(1):1\u201310.","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"3500_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13550-024-01115-4","volume":"14","author":"N Payan","year":"2024","unstructured":"Payan N, Presles B, Coutant C, Desmoulins I, Ladoire S, Beltjens F, et al. Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and triple negative breast cancer. EJNMMI Res. 2024;14(1):60.","journal-title":"EJNMMI Res"},{"issue":"6","key":"3500_CR46","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2967\/jnumed.119.237446","volume":"61","author":"JR Barrio","year":"2020","unstructured":"Barrio JR, Huang SC, Satyamurthy N, Scafoglio CS, Yu AS, Alavi A, et al. Does 2-FDG PET accurately reflect quantitative in vivo glucose utilization?? J Nucl Med. 2020;61(6):931\u20137.","journal-title":"J Nucl Med"},{"key":"3500_CR47","doi-asserted-by":"publisher","first-page":"601053","DOI":"10.3389\/fonc.2021.601053","volume":"11","author":"L Fantini","year":"2021","unstructured":"Fantini L, Belli ML, Azzali I, Loi E, Bettinelli A, Feliciani G, et al. Exploratory analysis of (18)F-3\u2019-deoxy-3\u2019-fluorothymidine ((18)F-FLT) PET\/CT-Based radiomics for the early evaluation of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Front Oncol. 2021;11:601053.","journal-title":"Front Oncol"},{"issue":"11","key":"3500_CR48","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.2967\/jnumed.115.160663","volume":"56","author":"L Kostakoglu","year":"2015","unstructured":"Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, et al. A phase II study of 3\u2019-Deoxy-3\u2019-18F-Fluorothymidine PET in the assessment of early response of breast cancer to neoadjuvant chemotherapy: results from ACRIN 6688. J Nucl Med. 2015;56(11):1681\u20139.","journal-title":"J Nucl Med"},{"issue":"8","key":"3500_CR49","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1021\/acs.molpharmaceut.8b00430","volume":"15","author":"F Liu","year":"2018","unstructured":"Liu F, Xu X, Zhu H, Zhang Y, Yang J, Zhang L, et al. PET imaging of (18)F-(2 S,4 R)4-Fluoroglutamine accumulation in breast cancer: from xenografts to patients. Mol Pharm. 2018;15(8):3448\u201355.","journal-title":"Mol Pharm"},{"issue":"1","key":"3500_CR50","first-page":"33","volume":"2","author":"I Grassi","year":"2012","unstructured":"Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, Castellucci P, et al. The clinical use of PET with (11)C-acetate. Am J Nucl Med Mol Imaging. 2012;2(1):33\u201347.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"6","key":"3500_CR51","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.annonc.2024.02.007","volume":"35","author":"A Gennari","year":"2024","unstructured":"Gennari A, Brain E, De Censi A, Nanni O, Wuerstlein R, Frassoldati A, et al. Early prediction of endocrine responsiveness in ER+\/HER2-negative metastatic breast cancer (MBC): pilot study with (18)F-fluoroestradiol ((18)F-FES) CT\/PET. Ann Oncol. 2024;35(6):549\u201358.","journal-title":"Ann Oncol"},{"issue":"5","key":"3500_CR52","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.semnuclmed.2022.03.002","volume":"52","author":"GA Ulaner","year":"2022","unstructured":"Ulaner GA. 16alpha-18F-fluoro-17beta-Fluoroestradiol (FES): clinical applications for patients with breast cancer. Semin Nucl Med. 2022;52(5):574\u201383.","journal-title":"Semin Nucl Med"},{"issue":"4","key":"3500_CR53","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/jmri.26042","volume":"48","author":"S Drisis","year":"2018","unstructured":"Drisis S, Flamen P, Ignatiadis M, Metens T, Chao SL, Chintinne M, et al. Total choline quantification measured by 1H MR spectroscopy as early predictor of response after neoadjuvant treatment for locally advanced breast cancer: the impact of immunohistochemical status. J Magn Reson Imaging. 2018;48(4):982\u201393.","journal-title":"J Magn Reson Imaging"},{"key":"3500_CR54","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3389\/fonc.2018.00319","volume":"8","author":"U Sharma","year":"2018","unstructured":"Sharma U, Agarwal K, Sah RG, Parshad R, Seenu V, Mathur S, et al. Can Multi-Parametric MR based approach improve the predictive value of pathological and clinical therapeutic response in breast cancer patients?? Front Oncol. 2018;8:319.","journal-title":"Front Oncol"},{"issue":"23","key":"3500_CR55","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1158\/0008-5472.CAN-21-1499","volume":"81","author":"R Woitek","year":"2021","unstructured":"Woitek R, McLean MA, Ursprung S, Rueda OM, Manzano Garcia R, Locke MJ, et al. Hyperpolarized Carbon-13 MRI for early response assessment of neoadjuvant chemotherapy in breast cancer patients. Cancer Res. 2021;81(23):6004\u201317.","journal-title":"Cancer Res"},{"issue":"4","key":"3500_CR56","doi-asserted-by":"publisher","first-page":"e200017","DOI":"10.1148\/rycan.2020200017","volume":"2","author":"R Woitek","year":"2020","unstructured":"Woitek R, McLean MA, Gill AB, Grist JT, Provenzano E, Patterson AJ, et al. Hyperpolarized (13)C MRI of tumor metabolism demonstrates early metabolic response to neoadjuvant chemotherapy in breast cancer. Radiol Imaging Cancer. 2020;2(4):e200017.","journal-title":"Radiol Imaging Cancer"},{"issue":"2","key":"3500_CR57","doi-asserted-by":"publisher","first-page":"e1550","DOI":"10.1002\/ctm2.1550","volume":"14","author":"Q Yang","year":"2024","unstructured":"Yang Q, Deng S, Preibsch H, Schade TC, Koch A, Berezhnoy G, et al. Image-guided metabolomics and transcriptomics reveal tumour heterogeneity in luminal A and B human breast cancer beyond glucose tracer uptake. Clin Transl Med. 2024;14(2):e1550.","journal-title":"Clin Transl Med"},{"key":"3500_CR58","doi-asserted-by":"publisher","first-page":"708052","DOI":"10.3389\/fmolb.2021.708052","volume":"8","author":"X He","year":"2021","unstructured":"He X, Gu J, Zou D, Yang H, Zhang Y, Ding Y, et al. NMR-Based metabolomics analysis predicts response to neoadjuvant chemotherapy for Triple-Negative breast cancer. Front Mol Biosci. 2021;8:708052.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"3500_CR59","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2012.10.003","volume":"7","author":"S Wei","year":"2013","unstructured":"Wei S, Liu L, Zhang J, Bowers J, Gowda GA, Seeger H, et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol. 2013;7(3):297\u2013307.","journal-title":"Mol Oncol"},{"issue":"22","key":"3500_CR60","doi-asserted-by":"publisher","first-page":"670","DOI":"10.21037\/atm.2019.10.34","volume":"7","author":"X Lin","year":"2019","unstructured":"Lin X, Xu R, Mao S, Zhang Y, Dai Y, Guo Q, et al. Metabolic biomarker signature for predicting the effect of neoadjuvant chemotherapy of breast cancer. Ann Transl Med. 2019;7(22):670.","journal-title":"Ann Transl Med"},{"key":"3500_CR61","doi-asserted-by":"crossref","unstructured":"Vignoli A, Muraro E, Miolo G, Tenori L, Turano P, Di Gregorio E et al. Effect of Estrogen receptor status on circulatory immune and metabolomics profiles of HER2-Positive breast cancer patients enrolled for neoadjuvant targeted chemotherapy. Cancers (Basel). 2020;12(2):314.","DOI":"10.3390\/cancers12020314"},{"key":"3500_CR62","doi-asserted-by":"publisher","first-page":"876100","DOI":"10.3389\/frai.2022.876100","volume":"5","author":"E Irajizad","year":"2022","unstructured":"Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, et al. Application of artificial intelligence to plasma metabolomics profiles to predict response to neoadjuvant chemotherapy in Triple-Negative breast cancer. Front Artif Intell. 2022;5:876100.","journal-title":"Front Artif Intell"},{"issue":"7","key":"3500_CR63","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11306-023-02024-8","volume":"19","author":"A Zapater-Moros","year":"2023","unstructured":"Zapater-Moros A, Diaz-Beltran L, Gamez-Pozo A, Trilla-Fuertes L, Lumbreras-Herrera MI, Lopez-Camacho E, et al. Metabolomics unravels subtype-specific characteristics related to neoadjuvant therapy response in breast cancer patients. Metabolomics. 2023;19(7):60.","journal-title":"Metabolomics"},{"key":"3500_CR64","doi-asserted-by":"crossref","unstructured":"Silva AAR, Cardoso MR, Oliveira DC, Godoy P, Talarico MCR, Gutierrez JM et al. Plasma metabolome signatures to predict responsiveness to neoadjuvant chemotherapy in breast cancer. Cancers (Basel). 2024;16(13):2473.","DOI":"10.3390\/cancers16132473"},{"issue":"2","key":"3500_CR65","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10549-024-07370-2","volume":"207","author":"M Yamada","year":"2024","unstructured":"Yamada M, Jinno H, Naruse S, Isono Y, Maeda Y, Sato A, et al. Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics. Breast Cancer Res Treat. 2024;207(2):393\u2013404.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"3500_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11306-025-02230-6","volume":"21","author":"R Nambo-Venegas","year":"2025","unstructured":"Nambo-Venegas R, Enriquez-Carcamo VI, Vela-Amieva M, Ibarra-Gonzalez I, Lopez-Castro L, Cabrera-Nieto SA, et al. A predictive model for neoadjuvant therapy response in breast cancer. Metabolomics. 2025;21(2):28.","journal-title":"Metabolomics"},{"issue":"1","key":"3500_CR67","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13058-024-01813-w","volume":"26","author":"N Zhang","year":"2024","unstructured":"Zhang N, Huang Y, Wang G, Xiang Y, Jing Z, Zeng J, et al. Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2\u2009+\u2009breast cancer. Breast Cancer Res. 2024;26(1):64.","journal-title":"Breast Cancer Res"},{"key":"3500_CR68","doi-asserted-by":"crossref","unstructured":"Joshi S, Garlapati C, Bhattarai S, Su Y, Rios-Colon L, Deep G et al. Exosomal metabolic signatures are associated with differential response to neoadjuvant chemotherapy in patients with breast cancer. Int J Mol Sci. 2022;23(10):5324.","DOI":"10.3390\/ijms23105324"},{"key":"3500_CR69","doi-asserted-by":"crossref","unstructured":"Zidi O, Souai N, Raies H, Ben Ayed F, Mezlini A, Mezrioui S et al. Fecal metabolic profiling of breast cancer patients during neoadjuvant chemotherapy reveals potential biomarkers. Molecules. 2021;26(8):2266.","DOI":"10.3390\/molecules26082266"},{"issue":"10","key":"3500_CR70","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1021\/acs.jproteome.0c00362","volume":"19","author":"C Lo","year":"2020","unstructured":"Lo C, Hsu YL, Cheng CN, Lin CH, Kuo HC, Huang CS, et al. Investigating the association of the biogenic amine profile in urine with therapeutic response to neoadjuvant chemotherapy in breast cancer patients. J Proteome Res. 2020;19(10):4061\u201370.","journal-title":"J Proteome Res"},{"issue":"9","key":"3500_CR71","doi-asserted-by":"publisher","first-page":"e9443","DOI":"10.15252\/msb.20209443","volume":"16","author":"A Shenoy","year":"2020","unstructured":"Shenoy A, Belugali Nataraj N, Perry G, Loayza Puch F, Nagel R, Marin I, et al. Proteomic patterns associated with response to breast cancer neoadjuvant treatment. Mol Syst Biol. 2020;16(9):e9443.","journal-title":"Mol Syst Biol"},{"key":"3500_CR72","doi-asserted-by":"crossref","unstructured":"Gwark S, Ahn HS, Yeom J, Yu J, Oh Y, Jeong JH et al. Plasma proteome signature to predict the outcome of breast cancer patients receiving neoadjuvant chemotherapy. Cancers (Basel). 2021;13(24):6267.","DOI":"10.3390\/cancers13246267"},{"issue":"11","key":"3500_CR73","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1158\/2159-8290.CD-22-0200","volume":"12","author":"M Anurag","year":"2022","unstructured":"Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, et al. Proteogenomic markers of chemotherapy resistance and response in Triple-Negative breast cancer. Cancer Discov. 2022;12(11):2586\u2013605.","journal-title":"Cancer Discov"},{"issue":"4","key":"3500_CR74","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s43018-021-00190-z","volume":"2","author":"KL McNamara","year":"2021","unstructured":"McNamara KL, Caswell-Jin JL, Joshi R, Ma Z, Kotler E, Bean GR, et al. Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nat Cancer. 2021;2(4):400\u201313.","journal-title":"Nat Cancer"},{"issue":"1","key":"3500_CR75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13058-024-01788-8","volume":"26","author":"F Derouane","year":"2024","unstructured":"Derouane F, Desgres M, Moroni C, Ambroise J, Berliere M, Van Bockstal MR, et al. Metabolic adaptation towards Glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers. Breast Cancer Res. 2024;26(1):29.","journal-title":"Breast Cancer Res"},{"issue":"13","key":"3500_CR76","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1158\/1078-0432.CCR-13-0623","volume":"19","author":"JB Dennison","year":"2013","unstructured":"Dennison JB, Molina JR, Mitra S, Gonzalez-Angulo AM, Balko JM, Kuba MG, et al. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2013;19(13):3703\u201313.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"3500_CR77","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1158\/0008-5472.CAN-20-3242","volume":"81","author":"KW Evans","year":"2021","unstructured":"Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, et al. Oxidative phosphorylation is a metabolic vulnerability in Chemotherapy-Resistant Triple-Negative breast cancer. Cancer Res. 2021;81(21):5572\u201381.","journal-title":"Cancer Res"},{"key":"3500_CR78","doi-asserted-by":"publisher","first-page":"102016","DOI":"10.1016\/j.tranon.2024.102016","volume":"46","author":"X Wang","year":"2024","unstructured":"Wang X, Chi W, Ma Y, Zhang Q, Xue J, Shao ZM, et al. DUSP4 enhances therapeutic sensitivity in HER2-positive breast cancer by inhibiting the G6PD pathway and ROS metabolism by interacting with ALDOB. Transl Oncol. 2024;46:102016.","journal-title":"Transl Oncol"},{"issue":"1","key":"3500_CR79","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13058-020-01350-2","volume":"22","author":"S Han","year":"2020","unstructured":"Han S, Choi JY. Prognostic value of (18)F-FDG PET and PET\/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2020;22(1):119.","journal-title":"Breast Cancer Res"},{"key":"3500_CR80","doi-asserted-by":"crossref","unstructured":"Talarico MCR, Derchain S, da Silva LF, Sforca ML, Rocco SA, Cardoso MR et al. Metabolomic profiling of breast cancer patients undergoing neoadjuvant chemotherapy for predicting Disease-Free and overall survival. Int J Mol Sci. 2024;25(16):8639.","DOI":"10.3390\/ijms25168639"},{"issue":"14","key":"3500_CR81","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1002\/1878-0261.13216","volume":"16","author":"C Diaz","year":"2022","unstructured":"Diaz C, Gonzalez-Olmedo C, Diaz-Beltran L, Camacho J, Mena Garcia P, Martin-Blazquez A, et al. Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach. Mol Oncol. 2022;16(14):2658\u201371.","journal-title":"Mol Oncol"},{"issue":"1","key":"3500_CR82","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-024-01956-w","volume":"27","author":"Z Fang","year":"2025","unstructured":"Fang Z, Ren G, Ke S, Xu Q, Chen Y, Shi X, et al. Serum metabolomic profiling for predicting therapeutic response and toxicity in breast cancer neoadjuvant chemotherapy: a retrospective longitudinal study. Breast Cancer Res. 2025;27(1):2.","journal-title":"Breast Cancer Res"},{"key":"3500_CR83","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2407-12-39","volume":"12","author":"MD Cao","year":"2012","unstructured":"Cao MD, Giskeodegard GF, Bathen TF, Sitter B, Bofin A, Lonning PE, et al. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer. 2012;12:39.","journal-title":"BMC Cancer"},{"key":"3500_CR84","doi-asserted-by":"crossref","unstructured":"Menyhart O, Fekete JT, Gyorffy B. Resistance to combined Anthracycline-Taxane chemotherapy is associated with altered metabolism and inflammation in breast carcinomas. Int J Mol Sci. 2024;25(2):1063.","DOI":"10.3390\/ijms25021063"},{"issue":"1","key":"3500_CR85","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41523-022-00428-8","volume":"8","author":"M Hoogstraat","year":"2022","unstructured":"Hoogstraat M, Lips EH, Mayayo-Peralta I, Mulder L, Kristel P, van der Heijden I, et al. Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. NPJ Breast Cancer. 2022;8(1):60.","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"3500_CR86","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s13402-021-00634-9","volume":"44","author":"U Mehraj","year":"2021","unstructured":"Mehraj U, Ganai RA, Macha MA, Hamid A, Zargar MA, Bhat AA, et al. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: new challenges and therapeutic opportunities. Cell Oncol (Dordr). 2021;44(6):1209\u201329.","journal-title":"Cell Oncol (Dordr)"},{"issue":"35","key":"3500_CR87","doi-asserted-by":"publisher","first-page":"e2205456119","DOI":"10.1073\/pnas.2205456119","volume":"119","author":"F Roshanzamir","year":"2022","unstructured":"Roshanzamir F, Robinson JL, Cook D, Karimi-Jafari MH, Nielsen J. Metastatic triple negative breast cancer adapts its metabolism to destination tissues while retaining key metabolic signatures. Proc Natl Acad Sci U S A. 2022;119(35):e2205456119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3500_CR88","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.drup.2021.100797","volume":"59","author":"AC Goncalves","year":"2021","unstructured":"Goncalves AC, Richiardone E, Jorge J, Polonia B, Xavier CPR, Salaroglio IC, et al. Impact of cancer metabolism on therapy resistance - Clinical implications. Drug Resist Updat. 2021;59:100797.","journal-title":"Drug Resist Updat"},{"issue":"4","key":"3500_CR89","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","volume":"183","author":"S Shen","year":"2020","unstructured":"Shen S, Vagner S, Robert C. Persistent cancer cells: the deadly survivors. Cell. 2020;183(4):860\u201374.","journal-title":"Cell"},{"key":"3500_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","volume":"38","author":"P Icard","year":"2018","unstructured":"Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1\u201311.","journal-title":"Drug Resist Updat"},{"key":"3500_CR91","doi-asserted-by":"publisher","first-page":"652266","DOI":"10.3389\/fonc.2021.652266","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang H, Wang M, Schmid T, Xin Z, Kozhuharova L, et al. Hypoxia in breast Cancer-Scientific translation to therapeutic and diagnostic clinical applications. Front Oncol. 2021;11:652266.","journal-title":"Front Oncol"},{"key":"3500_CR92","doi-asserted-by":"crossref","unstructured":"Costin IC, Marcu LG. Affinity of PET-MRI tracers for hypoxic cells in breast cancer: A systematic review. Cells. 2024;13(12):1048.","DOI":"10.3390\/cells13121048"},{"issue":"1","key":"3500_CR93","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13058-018-0970-6","volume":"20","author":"A Asano","year":"2018","unstructured":"Asano A, Ueda S, Kuji I, Yamane T, Takeuchi H, Hirokawa E, et al. Intracellular hypoxia measured by (18)F-fluoromisonidazole positron emission tomography has prognostic impact in patients with Estrogen receptor-positive breast cancer. Breast Cancer Res. 2018;20(1):78.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"3500_CR94","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-16-0738","volume":"23","author":"M Quintela-Fandino","year":"2017","unstructured":"Quintela-Fandino M, Lluch A, Manso L, Calvo I, Cortes J, Garcia-Saenz JA, et al. (18)F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-Negative breast cancer: A Window-of-Opportunity randomized trial. Clin Cancer Res. 2017;23(6):1432\u201341.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3500_CR95","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/jmri.23891","volume":"37","author":"L Jiang","year":"2013","unstructured":"Jiang L, Weatherall PT, McColl RW, Tripathy D, Mason RP. Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study. J Magn Reson Imaging. 2013;37(5):1083\u201392.","journal-title":"J Magn Reson Imaging"},{"issue":"7","key":"3500_CR96","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1007\/s00330-016-4630-x","volume":"27","author":"R Bedair","year":"2017","unstructured":"Bedair R, Priest AN, Patterson AJ, McLean MA, Graves MJ, Manavaki R, et al. Assessment of early treatment response to neoadjuvant chemotherapy in breast cancer using non-mono-exponential diffusion models: a feasibility study comparing the baseline and mid-treatment MRI examinations. Eur Radiol. 2017;27(7):2726\u201336.","journal-title":"Eur Radiol"},{"issue":"1","key":"3500_CR97","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13058-023-01607-6","volume":"25","author":"MV Pavlov","year":"2023","unstructured":"Pavlov MV, Bavrina AP, Plekhanov VI, Golubyatnikov GY, Orlova AG, Subochev PV, et al. Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy. Breast Cancer Res. 2023;25(1):12.","journal-title":"Breast Cancer Res"},{"key":"3500_CR98","doi-asserted-by":"publisher","first-page":"1277556","DOI":"10.3389\/fonc.2023.1277556","volume":"13","author":"SM Cheung","year":"2023","unstructured":"Cheung SM, Wu WS, Senn N, Sharma R, McGoldrick T, Gagliardi T, et al. Towards detection of early response in neoadjuvant chemotherapy of breast cancer using bayesian intravoxel incoherent motion. Front Oncol. 2023;13:1277556.","journal-title":"Front Oncol"},{"key":"3500_CR99","doi-asserted-by":"crossref","unstructured":"Cheung SM, Chan KS, Senn N, Husain E, Sharma R, McGoldrick T et al. Peri-Tumoural lipid composition and hypoxia for early immune response to neoadjuvant chemotherapy in breast cancer. Int J Mol Sci. 2024;25(17):9303.","DOI":"10.3390\/ijms25179303"},{"key":"3500_CR100","doi-asserted-by":"crossref","unstructured":"Ramirez-Tortosa CL, Alonso-Calderon R, Galvez-Navas JM, Perez-Ramirez C, Quiles JL, Sanchez-Rovira P et al. Hypoxia-Inducible Factor-1 alpha expression is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. Cancers (Basel). 2022;14(21):5393.","DOI":"10.3390\/cancers14215393"},{"issue":"5","key":"3500_CR101","doi-asserted-by":"publisher","first-page":"592","DOI":"10.6061\/clinics\/2013(05)03","volume":"68","author":"DG Tiezzi","year":"2013","unstructured":"Tiezzi DG, Clagnan WS, Mandarano LR, de Sousa CB, Marana HR, Tiezzi MG, et al. Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer. Clin (Sao Paulo). 2013;68(5):592\u20138.","journal-title":"Clin (Sao Paulo)"},{"issue":"51","key":"3500_CR102","doi-asserted-by":"publisher","first-page":"e13551","DOI":"10.1097\/MD.0000000000013551","volume":"97","author":"C Nie","year":"2018","unstructured":"Nie C, Lv H, Bie L, Hou H, Chen X. Hypoxia-inducible factor 1-alpha expression correlates with response to neoadjuvant chemotherapy in women with breast cancer. Med (Baltim). 2018;97(51):e13551.","journal-title":"Med (Baltim)"},{"key":"3500_CR103","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.2147\/CMAR.S246349","volume":"12","author":"J Zhang","year":"2020","unstructured":"Zhang J, Zhang S, Gao S, Ma Y, Tan X, Kang Y, et al. HIF-1alpha, TWIST-1 and ITGB-1, associated with tumor stiffness, as novel predictive markers for the pathological response to neoadjuvant chemotherapy in breast cancer. Cancer Manag Res. 2020;12:2209\u201322.","journal-title":"Cancer Manag Res"},{"issue":"45","key":"3500_CR104","doi-asserted-by":"publisher","first-page":"78870","DOI":"10.18632\/oncotarget.20239","volume":"8","author":"M Milani","year":"2017","unstructured":"Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, et al. Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget. 2017;8(45):78870\u201381.","journal-title":"Oncotarget"},{"issue":"5","key":"3500_CR105","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00428-023-03527-4","volume":"482","author":"DM El-Guindy","year":"2023","unstructured":"El-Guindy DM, Ibrahim FM, Ali DA, El-Horany HE, Sabry NM, Elkholy RA, et al. Hypoxia-induced autophagy in triple negative breast cancer: association with prognostic variables, patients\u2019 survival and response to neoadjuvant chemotherapy. Virchows Arch. 2023;482(5):823\u201337.","journal-title":"Virchows Arch"},{"key":"3500_CR106","doi-asserted-by":"publisher","first-page":"729965","DOI":"10.3389\/fcell.2021.729965","volume":"9","author":"H Dai","year":"2021","unstructured":"Dai H, Sheng X, Wang Y, Zhou L, Lin Y, Du Y, et al. HIF1alpha regulates IL17 signaling pathway influencing sensitivity of Taxane-Based chemotherapy for breast cancer. Front Cell Dev Biol. 2021;9:729965.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"3500_CR107","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1677\/erc.1.01216","volume":"13","author":"D Generali","year":"2006","unstructured":"Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, et al. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin\/tamoxifen therapy for breast cancer. Endocr Relat Cancer. 2006;13(3):921\u201330.","journal-title":"Endocr Relat Cancer"},{"issue":"15","key":"3500_CR108","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/1078-0432.CCR-05-2690","volume":"12","author":"D Generali","year":"2006","unstructured":"Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res. 2006;12(15):4562\u20138.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3500_CR109","first-page":"9555","volume":"9","author":"L Mo","year":"2016","unstructured":"Mo L, Chen Q, Yang Y, Rui X, Gu J. High expression of GLUT1 and GLUT3 correlate with neoadjuvant chemotherapy ineffectiveness breast cancer patients. Int J Clin Exp Pathol. 2016;9(9):9555\u201361.","journal-title":"Int J Clin Exp Pathol"},{"issue":"8","key":"3500_CR110","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-19-1954","volume":"26","author":"T Karn","year":"2020","unstructured":"Karn T, Meissner T, Weber KE, Solbach C, Denkert C, Engels K, et al. A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial. Clin Cancer Res. 2020;26(8):1896\u2013904.","journal-title":"Clin Cancer Res"},{"issue":"33","key":"3500_CR111","doi-asserted-by":"publisher","first-page":"E4600","DOI":"10.1073\/pnas.1513433112","volume":"112","author":"H Lu","year":"2015","unstructured":"Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I, et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A. 2015;112(33):E4600\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"3500_CR112","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41418-022-00963-8","volume":"29","author":"Y Yan","year":"2022","unstructured":"Yan Y, He M, Zhao L, Wu H, Zhao Y, Han L, et al. A novel HIF-2alpha targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI\/GPR78-UPR(ER) axis. Cell Death Differ. 2022;29(9):1769\u201389.","journal-title":"Cell Death Differ"},{"issue":"34","key":"3500_CR113","doi-asserted-by":"publisher","first-page":"e2403831","DOI":"10.1002\/advs.202403831","volume":"11","author":"FM Barnieh","year":"2024","unstructured":"Barnieh FM, Morais GR, Loadman PM, Falconer RA, El-Khamisy SF. Hypoxia-Responsive prodrug of ATR inhibitor, AZD6738, selectively eradicates Treatment-Resistant cancer cells. Adv Sci (Weinh). 2024;11(34):e2403831.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"3500_CR114","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0027-5107(92)90235-T","volume":"268","author":"T Morita","year":"1992","unstructured":"Morita T, Nagaki T, Fukuda I, Okumura K. Clastogenicity of low pH to various cultured mammalian cells. Mutat Res. 1992;268(2):297\u2013305.","journal-title":"Mutat Res"},{"issue":"3","key":"3500_CR115","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s44319-024-00089-7","volume":"25","author":"L Aubert","year":"2024","unstructured":"Aubert L, Bastien E, Renoult O, Guilbaud C, Ozkan K, Brusa D, et al. Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors. EMBO Rep. 2024;25(3):1469\u201389.","journal-title":"EMBO Rep"},{"issue":"12","key":"3500_CR116","doi-asserted-by":"publisher","first-page":"e1000293","DOI":"10.1371\/journal.pgen.1000293","volume":"4","author":"JL Chen","year":"2008","unstructured":"Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J, et al. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet. 2008;4(12):e1000293.","journal-title":"PLoS Genet"},{"key":"3500_CR117","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fonc.2019.00159","volume":"9","author":"C Vander Linden","year":"2019","unstructured":"Vander Linden C, Corbet C. Therapeutic targeting of cancer stem cells: integrating and exploiting the acidic niche. Front Oncol. 2019;9:159.","journal-title":"Front Oncol"},{"issue":"10","key":"3500_CR118","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00109-020-01959-y","volume":"98","author":"E Andreucci","year":"2020","unstructured":"Andreucci E, Peppicelli S, Ruzzolini J, Bianchini F, Biagioni A, Papucci L, et al. The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells. J Mol Med (Berl). 2020;98(10):1431\u201346.","journal-title":"J Mol Med (Berl)"},{"issue":"7","key":"3500_CR119","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S0006-2952(03)00467-2","volume":"66","author":"BP Mahoney","year":"2003","unstructured":"Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 2003;66(7):1207\u201318.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"3500_CR120","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1021\/mp200292c","volume":"8","author":"JW Wojtkowiak","year":"2011","unstructured":"Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm. 2011;8(6):2032\u20138.","journal-title":"Mol Pharm"},{"key":"3500_CR121","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.drup.2015.08.004","volume":"23","author":"S Taylor","year":"2015","unstructured":"Taylor S, Spugnini EP, Assaraf YG, Azzarito T, Rauch C, Fais S. Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat. 2015;23:69\u201378.","journal-title":"Drug Resist Updat"},{"issue":"22","key":"3500_CR122","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/jnci\/djh305","volume":"96","author":"F Luciani","year":"2004","unstructured":"Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96(22):1702\u201313.","journal-title":"J Natl Cancer Inst"},{"issue":"39","key":"3500_CR123","doi-asserted-by":"publisher","first-page":"63408","DOI":"10.18632\/oncotarget.11503","volume":"7","author":"S Avnet","year":"2016","unstructured":"Avnet S, Lemma S, Cortini M, Pellegrini P, Perut F, Zini N, et al. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance. Oncotarget. 2016;7(39):63408\u201323.","journal-title":"Oncotarget"},{"key":"3500_CR124","doi-asserted-by":"crossref","unstructured":"Tavares-Valente D, Sousa B, Schmitt F, Baltazar F, Queiros O. Disruption of pH dynamics suppresses proliferation and potentiates doxorubicin cytotoxicity in breast cancer cells. Pharmaceutics. 2021;13(2):242.","DOI":"10.3390\/pharmaceutics13020242"},{"key":"3500_CR125","first-page":"746025","volume":"2012","author":"GM Cheng","year":"2012","unstructured":"Cheng GM, To KK. Adverse cell culture conditions mimicking the tumor microenvironment upregulate ABCG2 to mediate multidrug resistance and a more malignant phenotype. ISRN Oncol. 2012;2012:746025.","journal-title":"ISRN Oncol"},{"key":"3500_CR126","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-4939-0620-8_7","volume":"812","author":"O Thews","year":"2014","unstructured":"Thews O, Riemann A, Nowak M, Gekle M. Impact of hypoxia-related tumor acidosis on cytotoxicity of different chemotherapeutic drugs in vitro and in vivo. Adv Exp Med Biol. 2014;812:51\u20138.","journal-title":"Adv Exp Med Biol"},{"key":"3500_CR127","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-4419-7756-4_16","volume":"701","author":"O Thews","year":"2011","unstructured":"Thews O, Nowak M, Sauvant C, Gekle M. Hypoxia-induced extracellular acidosis increases p-glycoprotein activity and chemoresistance in tumors in vivo via p38 signaling pathway. Adv Exp Med Biol. 2011;701:115\u201322.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"3500_CR128","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1593\/neo.05697","volume":"8","author":"O Thews","year":"2006","unstructured":"Thews O, Gassner B, Kelleher DK, Schwerdt G, Gekle M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia. 2006;8(2):143\u201352.","journal-title":"Neoplasia"},{"issue":"11","key":"3500_CR129","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1002\/ijc.23818","volume":"123","author":"C Sauvant","year":"2008","unstructured":"Sauvant C, Nowak M, Wirth C, Schneider B, Riemann A, Gekle M, et al. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. Int J Cancer. 2008;123(11):2532\u201342.","journal-title":"Int J Cancer"},{"issue":"6","key":"3500_CR130","doi-asserted-by":"publisher","first-page":"e101053","DOI":"10.1371\/journal.pone.0101053","volume":"9","author":"F Visioli","year":"2014","unstructured":"Visioli F, Wang Y, Alam GN, Ning Y, Rados PV, Nor JE, et al. Glucose-regulated protein 78 (Grp78) confers chemoresistance to tumor endothelial cells under acidic stress. PLoS ONE. 2014;9(6):e101053.","journal-title":"PLoS ONE"},{"issue":"3","key":"3500_CR131","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12192-014-0568-6","volume":"20","author":"V Sharma","year":"2015","unstructured":"Sharma V, Kaur R, Bhatnagar A, Kaur J. Low-pH-induced apoptosis: role of Endoplasmic reticulum stress-induced calcium permeability and mitochondria-dependent signaling. Cell Stress Chaperones. 2015;20(3):431\u201340.","journal-title":"Cell Stress Chaperones"},{"key":"3500_CR132","doi-asserted-by":"crossref","unstructured":"Dong L, Krewson EA, Yang LV. Acidosis activates Endoplasmic reticulum stress pathways through GPR4 in human vascular endothelial cells. Int J Mol Sci. 2017;18(2):278.","DOI":"10.3390\/ijms18020278"},{"issue":"16","key":"3500_CR133","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1158\/0008-5472.CAN-11-3881","volume":"72","author":"JW Wojtkowiak","year":"2012","unstructured":"Wojtkowiak JW, Rothberg JM, Kumar V, Schramm KJ, Haller E, Proemsey JB, et al. Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res. 2012;72(16):3938\u201347.","journal-title":"Cancer Res"},{"issue":"36","key":"3500_CR134","doi-asserted-by":"publisher","first-page":"30664","DOI":"10.1074\/jbc.M112.339127","volume":"287","author":"ML Marino","year":"2012","unstructured":"Marino ML, Pellegrini P, Di Lernia G, Djavaheri-Mergny M, Brnjic S, Zhang X, et al. Autophagy is a protective mechanism for human melanoma cells under acidic stress. J Biol Chem. 2012;287(36):30664\u201376.","journal-title":"J Biol Chem"},{"issue":"1","key":"3500_CR135","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/2049-3002-1-23","volume":"1","author":"G Lamonte","year":"2013","unstructured":"Lamonte G, Tang X, Chen JL, Wu J, Ding CK, Keenan MM, et al. Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress. Cancer Metab. 2013;1(1):23.","journal-title":"Cancer Metab"},{"issue":"19","key":"3500_CR136","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1158\/0008-5472.CAN-14-0705","volume":"74","author":"C Corbet","year":"2014","unstructured":"Corbet C, Draoui N, Polet F, Pinto A, Drozak X, Riant O, et al. The SIRT1\/HIF2alpha axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy. Cancer Res. 2014;74(19):5507\u201319.","journal-title":"Cancer Res"},{"issue":"8","key":"3500_CR137","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cmet.2021.05.016","volume":"33","author":"E Dierge","year":"2021","unstructured":"Dierge E, Debock E, Guilbaud C, Corbet C, Mignolet E, Mignard L, et al. Peroxidation of n-3 and n-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects. Cell Metab. 2021;33(8):1701\u2013e155.","journal-title":"Cell Metab"},{"issue":"2","key":"3500_CR138","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cmet.2016.07.003","volume":"24","author":"C Corbet","year":"2016","unstructured":"Corbet C, Pinto A, Martherus R, Santiago de Jesus JP, Polet F, Feron O. Acidosis drives the reprogramming of fatty acid metabolism in cancer cells through changes in mitochondrial and histone acetylation. Cell Metab. 2016;24(2):311\u201323.","journal-title":"Cell Metab"},{"issue":"1","key":"3500_CR139","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41467-019-14262-3","volume":"11","author":"C Corbet","year":"2020","unstructured":"Corbet C, Bastien E, Santiago de Jesus JP, Dierge E, Martherus R, Vander Linden C, et al. TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 2020;11(1):454.","journal-title":"Nat Commun"},{"issue":"8","key":"3500_CR140","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/ijc.34404","volume":"152","author":"MG Rolver","year":"2023","unstructured":"Rolver MG, Holland LKK, Ponniah M, Prasad NS, Yao J, Schnipper J, et al. Chronic acidosis rewires cancer cell metabolism through PPARalpha signaling. Int J Cancer. 2023;152(8):1668\u201384.","journal-title":"Int J Cancer"},{"key":"3500_CR141","doi-asserted-by":"publisher","first-page":"122575","DOI":"10.1016\/j.ijpharm.2022.122575","volume":"632","author":"S Scialla","year":"2023","unstructured":"Scialla S, Hanafy MS, Wang JL, Genicio N, Costa Da Silva M, Costa M, et al. Targeted treatment of triple-negative-breast cancer through pH-triggered tumour associated macrophages using smart theranostic nanoformulations. Int J Pharm. 2023;632:122575.","journal-title":"Int J Pharm"},{"issue":"8","key":"3500_CR142","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1021\/mp5002526","volume":"11","author":"RC Adochite","year":"2014","unstructured":"Adochite RC, Moshnikova A, Carlin SD, Guerrieri RA, Andreev OA, Lewis JS, et al. Targeting breast tumors with pH (low) insertion peptides. Mol Pharm. 2014;11(8):2896\u2013905.","journal-title":"Mol Pharm"},{"issue":"12","key":"3500_CR143","doi-asserted-by":"publisher","first-page":"E2811","DOI":"10.1073\/pnas.1715350115","volume":"115","author":"LC Wyatt","year":"2018","unstructured":"Wyatt LC, Moshnikova A, Crawford T, Engelman DM, Andreev OA, Reshetnyak YK. Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors. Proc Natl Acad Sci U S A. 2018;115(12):E2811\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3500_CR144","doi-asserted-by":"crossref","unstructured":"Zhao T, Huang G, Li Y, Yang S, Ramezani S, Lin Z et al. A Transistor-like pH nanoprobe for tumour detection and Image-guided surgery. Nat Biomed Eng. 2016;1:0006.","DOI":"10.1038\/s41551-016-0006"},{"issue":"1","key":"3500_CR145","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1038\/s41467-020-16814-4","volume":"11","author":"FJ Voskuil","year":"2020","unstructured":"Voskuil FJ, Steinkamp PJ, Zhao T, van der Vegt B, Koller M, Doff JJ, et al. Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery. Nat Commun. 2020;11(1):3257.","journal-title":"Nat Commun"},{"issue":"10","key":"3500_CR146","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc.2017.77","volume":"17","author":"C Corbet","year":"2017","unstructured":"Corbet C, Feron O. Tumour acidosis: from the passenger to the driver\u2019s seat. Nat Rev Cancer. 2017;17(10):577\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"28","key":"3500_CR147","doi-asserted-by":"publisher","first-page":"45759","DOI":"10.18632\/oncotarget.17404","volume":"8","author":"M Chen","year":"2017","unstructured":"Chen M, Chen C, Shen Z, Zhang X, Chen Y, Lin F, et al. Extracellular pH is a biomarker enabling detection of breast cancer and liver cancer using CEST MRI. Oncotarget. 2017;8(28):45759\u201367.","journal-title":"Oncotarget"},{"issue":"1","key":"3500_CR148","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41416-020-01173-0","volume":"124","author":"A Anemone","year":"2021","unstructured":"Anemone A, Consolino L, Conti L, Irrera P, Hsu MY, Villano D, et al. Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential. Br J Cancer. 2021;124(1):207\u201316.","journal-title":"Br J Cancer"},{"issue":"1","key":"3500_CR149","doi-asserted-by":"publisher","first-page":"8550","DOI":"10.1038\/s41598-019-44873-1","volume":"9","author":"S Roberts","year":"2019","unstructured":"Roberts S, Strome A, Choi C, Andreou C, Kossatz S, Brand C, et al. Acid specific dark quencher QC1 pHLIP for multi-spectral optoacoustic diagnoses of breast cancer. Sci Rep. 2019;9(1):8550.","journal-title":"Sci Rep"},{"issue":"10","key":"3500_CR150","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1541-7786.MCR-22-1004","volume":"21","author":"ED Sunassee","year":"2023","unstructured":"Sunassee ED, Jardim-Perassi BV, Madonna MC, Ordway B, Ramanujam N. Metabolic imaging as a tool to characterize chemoresistance and guide therapy in Triple-Negative breast cancer (TNBC). Mol Cancer Res. 2023;21(10):995\u20131009.","journal-title":"Mol Cancer Res"},{"key":"3500_CR151","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cells11172719","volume":"11","author":"D Kordias","year":"2022","unstructured":"Kordias D, Kostara CE, Papadaki S, Verigos J, Bairaktari E, Magklara A. Omics analysis of chemoresistant triple negative breast cancer cells reveals novel metabolic vulnerabilities. Cells. 2022;11:17.","journal-title":"Cells"},{"issue":"14","key":"3500_CR152","doi-asserted-by":"publisher","first-page":"eadj7540","DOI":"10.1126\/sciadv.adj7540","volume":"10","author":"ED Sunassee","year":"2024","unstructured":"Sunassee ED, Deutsch RJ, D\u2019Agostino VW, Castellano-Escuder P, Siebeneck EA, Ilkayeva O, et al. Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrence. Sci Adv. 2024;10(14):eadj7540.","journal-title":"Sci Adv"},{"key":"3500_CR153","doi-asserted-by":"publisher","first-page":"100974","DOI":"10.1016\/j.drup.2023.100974","volume":"69","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Shen H, Xu J, Fang Z, Wo G, Ma Y, et al. GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells. Drug Resist Updat. 2023;69:100974.","journal-title":"Drug Resist Updat"},{"issue":"14","key":"3500_CR154","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s41388-023-02596-8","volume":"42","author":"ML Baek","year":"2023","unstructured":"Baek ML, Lee J, Pendleton KE, Berner MJ, Goff EB, Tan L, et al. Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment. Oncogene. 2023;42(14):1117\u201331.","journal-title":"Oncogene"},{"key":"3500_CR155","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1476-4598-9-33","volume":"9","author":"M Zhou","year":"2010","unstructured":"Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 2010;9:33.","journal-title":"Mol Cancer"},{"issue":"12","key":"3500_CR156","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1158\/1541-7786.MCR-19-0264","volume":"17","author":"I Sirois","year":"2019","unstructured":"Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, et al. A unique morphological phenotype in chemoresistant Triple-Negative breast cancer reveals metabolic reprogramming and PLIN4 expression as a molecular vulnerability. Mol Cancer Res. 2019;17(12):2492\u2013507.","journal-title":"Mol Cancer Res"},{"issue":"9\u201310","key":"3500_CR157","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s10495-024-01952-7","volume":"29","author":"S Tang","year":"2024","unstructured":"Tang S, Wang Q, Sun K, Song Y, Liu R, Tan X, et al. Metabolic heterogeneity and potential immunotherapeutic responses revealed by Single-Cell transcriptomics of breast cancer. Apoptosis. 2024;29(9\u201310):1466\u201382.","journal-title":"Apoptosis"},{"key":"3500_CR158","doi-asserted-by":"publisher","first-page":"100806","DOI":"10.1016\/j.drup.2022.100806","volume":"60","author":"V Van den Bossche","year":"2022","unstructured":"Van den Bossche V, Zaryouh H, Vara-Messler M, Vignau J, Machiels JP, Wouters A, et al. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. Drug Resist Updat. 2022;60:100806.","journal-title":"Drug Resist Updat"},{"key":"3500_CR159","doi-asserted-by":"publisher","first-page":"216656","DOI":"10.1016\/j.canlet.2024.216656","volume":"585","author":"F Jia","year":"2024","unstructured":"Jia F, Sun S, Li J, Wang W, Huang H, Hu X, et al. Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing. Cancer Lett. 2024;585:216656.","journal-title":"Cancer Lett"},{"key":"3500_CR160","doi-asserted-by":"publisher","first-page":"1035667","DOI":"10.3389\/fimmu.2022.1035667","volume":"13","author":"J Wu","year":"2022","unstructured":"Wu J, Tian Y, Liu W, Zheng H, Xi Y, Yan Y, et al. A novel twelve-gene signature to predict neoadjuvant chemotherapy response and prognosis in breast cancer. Front Immunol. 2022;13:1035667.","journal-title":"Front Immunol"},{"issue":"21","key":"3500_CR161","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1158\/1078-0432.CCR-19-3685","volume":"26","author":"ML Axelrod","year":"2020","unstructured":"Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, et al. Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer. Clin Cancer Res. 2020;26(21):5668\u201381.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"3500_CR162","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/1078-0432.CCR-22-0543","volume":"28","author":"P Gazinska","year":"2022","unstructured":"Gazinska P, Milton C, Iacovacci J, Ward J, Buus R, Alaguthurai T, et al. Dynamic changes in the NK-, Neutrophil-, and B-cell immunophenotypes relevant in high metastatic risk post neoadjuvant Chemotherapy-Resistant early breast cancers. Clin Cancer Res. 2022;28(20):4494\u2013508.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3500_CR163","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1002\/cam4.5372","volume":"12","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Zhang H, Pan C, He G, Cui X, Yu X, et al. Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancer. Cancer Med. 2023;12(5):5846\u201358.","journal-title":"Cancer Med"},{"key":"3500_CR164","doi-asserted-by":"crossref","unstructured":"Katayama MLH, Vieira R, Andrade VP, Roela RA, Lima L, Kerr LM et al. Stromal cell signature associated with response to neoadjuvant chemotherapy in locally advanced breast cancer. Cells. 2019;8(12):1566.","DOI":"10.3390\/cells8121566"},{"issue":"1","key":"3500_CR165","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/2326-6066.CIR-23-0076","volume":"12","author":"B Donati","year":"2024","unstructured":"Donati B, Reggiani F, Torricelli F, Santandrea G, Rossi T, Bisagni A, et al. Spatial distribution of immune cells drives resistance to neoadjuvant chemotherapy in Triple-Negative breast cancer. Cancer Immunol Res. 2024;12(1):120\u201334.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"3500_CR166","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1097\/JS9.0000000000001360","volume":"110","author":"X Wang","year":"2024","unstructured":"Wang X, Chen B, Zhang H, Peng L, Liu X, Zhang Q, et al. Integrative analysis identifies molecular features of fibroblast and the significance of fibrosis on neoadjuvant chemotherapy response in breast cancer. Int J Surg. 2024;110(7):4083\u201395.","journal-title":"Int J Surg"},{"issue":"7","key":"3500_CR167","doi-asserted-by":"publisher","first-page":"e1779","DOI":"10.1002\/ctm2.1779","volume":"14","author":"Z Xia","year":"2024","unstructured":"Xia Z, Vermeulen S, Suwal U, Rappu P, Heino J, De Vuyst F, et al. Cancer-associated fibroblasts mediate resistance to neoadjuvant therapy in breast cancer. Clin Transl Med. 2024;14(7):e1779.","journal-title":"Clin Transl Med"},{"issue":"1","key":"3500_CR168","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nm.1908","volume":"15","author":"P Farmer","year":"2009","unstructured":"Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009;15(1):68\u201374.","journal-title":"Nat Med"},{"issue":"22","key":"3500_CR169","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-24-1518","volume":"30","author":"M Quintela-Fandino","year":"2024","unstructured":"Quintela-Fandino M, Bermejo B, Zamora E, Moreno F, Garcia-Saenz JA, Pernas S, et al. High mechanical conditioning by tumor extracellular matrix stiffness is a predictive biomarker for antifibrotic therapy in HER2-Negative breast cancer. Clin Cancer Res. 2024;30(22):5094\u2013104.","journal-title":"Clin Cancer Res"},{"key":"3500_CR170","doi-asserted-by":"publisher","first-page":"1348299","DOI":"10.3389\/fonc.2024.1348299","volume":"14","author":"L Ning","year":"2024","unstructured":"Ning L, Quan C, Wang Y, Wu Z, Yuan P, Xie N. scRNA-seq characterizing the heterogeneity of fibroblasts in breast cancer reveals a novel subtype SFRP4(+) CAF that inhibits migration and predicts prognosis. Front Oncol. 2024;14:1348299.","journal-title":"Front Oncol"},{"issue":"1","key":"3500_CR171","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13058-022-01543-x","volume":"24","author":"T Al-Tweigeri","year":"2022","unstructured":"Al-Tweigeri T, AlRaouji NN, Tulbah A, Arafah M, Aboussekhra M, Al-Mohanna F, et al. High AUF1 level in stromal fibroblasts promotes carcinogenesis and chemoresistance and predicts unfavorable prognosis among locally advanced breast cancer patients. Breast Cancer Res. 2022;24(1):46.","journal-title":"Breast Cancer Res"},{"issue":"22","key":"3500_CR172","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1158\/0008-5472.CAN-23-0398","volume":"83","author":"D Miroshnychenko","year":"2023","unstructured":"Miroshnychenko D, Miti T, Kumar P, Miller A, Laurie M, Giraldo N, et al. Stroma-Mediated breast cancer cell proliferation indirectly drives chemoresistance by accelerating tumor recovery between chemotherapy cycles. Cancer Res. 2023;83(22):3681\u201392.","journal-title":"Cancer Res"},{"key":"3500_CR173","doi-asserted-by":"publisher","first-page":"216842","DOI":"10.1016\/j.canlet.2024.216842","volume":"590","author":"K Li","year":"2024","unstructured":"Li K, Lin H, Liu A, Qiu C, Rao Z, Wang Z, et al. SOD1-high fibroblasts derived Exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG. Cancer Lett. 2024;590:216842.","journal-title":"Cancer Lett"},{"issue":"741","key":"3500_CR174","doi-asserted-by":"publisher","first-page":"eadj5705","DOI":"10.1126\/scitranslmed.adj5705","volume":"16","author":"G Fan","year":"2024","unstructured":"Fan G, Yu B, Tang L, Zhu R, Chen J, Zhu Y, et al. TSPAN8(+) myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. Sci Transl Med. 2024;16(741):eadj5705.","journal-title":"Sci Transl Med"},{"issue":"4","key":"3500_CR175","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","volume":"172","author":"S Su","year":"2018","unstructured":"Su S, Chen J, Yao H, Liu J, Yu S, Lao L, et al. CD10(+)GPR77(+) cancer-Associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841\u201356. e16.","journal-title":"Cell"},{"issue":"1","key":"3500_CR176","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41420-023-01768-5","volume":"10","author":"CM Lee","year":"2024","unstructured":"Lee CM, Hwang Y, Jeong JW, Kim M, Lee J, Bae SJ, et al. BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer. Cell Death Discov. 2024;10(1):5.","journal-title":"Cell Death Discov"},{"issue":"13","key":"3500_CR177","doi-asserted-by":"publisher","first-page":"10728","DOI":"10.18632\/oncotarget.3828","volume":"6","author":"M Peiris-Pages","year":"2015","unstructured":"Peiris-Pages M, Sotgia F, Lisanti MP. Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. Oncotarget. 2015;6(13):10728\u201345.","journal-title":"Oncotarget"},{"issue":"19","key":"3500_CR178","doi-asserted-by":"publisher","first-page":"e2101848","DOI":"10.1002\/advs.202101848","volume":"8","author":"S Yu","year":"2021","unstructured":"Yu S, Lu Y, Su A, Chen J, Li J, Zhou B, et al. A CD10-OGP membrane peptolytic signaling axis in fibroblasts regulates lipid metabolism of cancer stem cells via SCD1. Adv Sci (Weinh). 2021;8(19):e2101848.","journal-title":"Adv Sci (Weinh)"},{"issue":"12","key":"3500_CR179","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2967\/jnumed.123.266079","volume":"64","author":"L Chen","year":"2023","unstructured":"Chen L, Zheng S, Chen L, Xu S, Wu K, Kong L, et al. (68)Ga-Labeled fibroblast activation protein inhibitor PET\/CT for the early and late prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients: A prospective study. J Nucl Med. 2023;64(12):1899\u2013905.","journal-title":"J Nucl Med"},{"issue":"5","key":"3500_CR180","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2967\/jnumed.122.264871","volume":"64","author":"P Backhaus","year":"2023","unstructured":"Backhaus P, Burg MC, Asmus I, Pixberg M, Buther F, Breyholz HJ, et al. Initial results of (68)Ga-FAPI-46 PET\/MRI to assess response to neoadjuvant chemotherapy in breast cancer. J Nucl Med. 2023;64(5):717\u201323.","journal-title":"J Nucl Med"},{"issue":"1","key":"3500_CR181","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41523-022-00491-1","volume":"8","author":"F Li","year":"2022","unstructured":"Li F, Yang Y, Wei Y, Zhao Y, Fu J, Xiao X, et al. Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer. NPJ Breast Cancer. 2022;8(1):124.","journal-title":"NPJ Breast Cancer"},{"key":"3500_CR182","doi-asserted-by":"crossref","unstructured":"Wu C, Dong S, Huang R, Chen X. Cancer-Associated adipocytes and breast cancer: intertwining in the tumor microenvironment and challenges for cancer therapy. Cancers (Basel). 2023;15(3):726.","DOI":"10.3390\/cancers15030726"},{"issue":"1","key":"3500_CR183","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/21623945.2021.1979758","volume":"10","author":"I Mentoor","year":"2021","unstructured":"Mentoor I, Engelbrecht AM, van de Vyver M, van Jaarsveld PJ, Nell T. The paracrine effects of adipocytes on lipid metabolism in doxorubicin-treated triple negative breast cancer cells. Adipocyte. 2021;10(1):505\u201323.","journal-title":"Adipocyte"},{"issue":"1","key":"3500_CR184","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12944-023-01912-1","volume":"22","author":"J Wu","year":"2023","unstructured":"Wu J, Li J, Xu H, Qiu N, Huang X, Li H. Periostin drives extracellular matrix degradation, stemness, and chemoresistance by activating the MAPK\/ERK signaling pathway in triple-negative breast cancer cells. Lipids Health Dis. 2023;22(1):153.","journal-title":"Lipids Health Dis"},{"issue":"4","key":"3500_CR185","doi-asserted-by":"publisher","first-page":"e87489","DOI":"10.1172\/jci.insight.87489","volume":"2","author":"YY Wang","year":"2017","unstructured":"Wang YY, Attane C, Milhas D, Dirat B, Dauvillier S, Guerard A, et al. Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. JCI Insight. 2017;2(4):e87489.","journal-title":"JCI Insight"},{"issue":"1","key":"3500_CR186","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cmet.2017.11.001","volume":"27","author":"T Wang","year":"2018","unstructured":"Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, et al. JAK\/STAT3-Regulated fatty acid beta-Oxidation is critical for breast cancer stem cell Self-Renewal and chemoresistance. Cell Metab. 2018;27(1):136\u201350. e5.","journal-title":"Cell Metab"},{"issue":"1","key":"3500_CR187","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13046-022-02592-y","volume":"42","author":"A Ritter","year":"2023","unstructured":"Ritter A, Kreis NN, Roth S, Friemel A, Safdar BK, Hoock SC, et al. Cancer-educated mammary adipose tissue-derived stromal\/stem cells in obesity and breast cancer: Spatial regulation and function. J Exp Clin Cancer Res. 2023;42(1):35.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"3500_CR188","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1093\/jnci\/djab023","volume":"113","author":"AE Lohmann","year":"2021","unstructured":"Lohmann AE, Soldera SV, Pimentel I, Ribnikar D, Ennis M, Amir E, et al. Association of obesity with breast cancer outcome in relation to cancer subtypes: A Meta-Analysis. J Natl Cancer Inst. 2021;113(11):1465\u201375.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3500_CR189","doi-asserted-by":"publisher","first-page":"9922","DOI":"10.1038\/s41598-021-89385-z","volume":"11","author":"F Gourgue","year":"2021","unstructured":"Gourgue F, Derouane F, van Marcke C, Villar E, Dano H, Desmet L, et al. Tumor Apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients. Sci Rep. 2021;11(1):9922.","journal-title":"Sci Rep"},{"issue":"1","key":"3500_CR190","doi-asserted-by":"publisher","first-page":"21145","DOI":"10.1038\/s41598-022-25043-2","volume":"12","author":"F Acevedo","year":"2022","unstructured":"Acevedo F, Walbaum B, Muniz S, Petric M, Martinez R, Guerra C, et al. Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy. Sci Rep. 2022;12(1):21145.","journal-title":"Sci Rep"},{"issue":"25","key":"3500_CR191","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1200\/JCO.2007.14.4527","volume":"26","author":"JK Litton","year":"2008","unstructured":"Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008;26(25):4072\u20137.","journal-title":"J Clin Oncol"},{"key":"3500_CR192","doi-asserted-by":"crossref","unstructured":"Guliyev M, Alan O, Gunaltili M, Safarov S, Fidan MC, Alkan Sen G et al. Obesity is an independent prognostic factor that reduced pathological complete response in operable breast cancer patients. Med (Kaunas). 2024;60(12):1953.","DOI":"10.3390\/medicina60121953"},{"issue":"3","key":"3500_CR193","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10549-023-07214-5","volume":"204","author":"H Wang","year":"2024","unstructured":"Wang H, Yee D, Potter D, Jewett P, Yau C, Beckwith H, et al. Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial. Breast Cancer Res Treat. 2024;204(3):589\u201397.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3500_CR194","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/cam4.571","volume":"5","author":"T Iwase","year":"2016","unstructured":"Iwase T, Sangai T, Nagashima T, Sakakibara M, Sakakibara J, Hayama S, et al. Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. Cancer Med. 2016;5(1):41\u20138.","journal-title":"Cancer Med"},{"key":"3500_CR195","doi-asserted-by":"crossref","unstructured":"Cho HH, Park M, Park H, Ko ES, Hwang NY, Im YH et al. The Tumor-Fat interface volume of breast cancer on pretreatment MRI is associated with a pathologic response to neoadjuvant chemotherapy. Biology (Basel). 2020;9(11):391.","DOI":"10.3390\/biology9110391"},{"issue":"1","key":"3500_CR196","first-page":"10","volume":"42","author":"O Dulgar","year":"2023","unstructured":"Dulgar O, Ibisoglu EO, Ay S, Uslu H, Gumus M. Is adipose tissue metabolic activity a predictor of pathological responses to neoadjuvant treatment in breast cancer. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2023;42(1):10\u20135.","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"issue":"1","key":"3500_CR197","doi-asserted-by":"publisher","first-page":"12541","DOI":"10.1038\/s41598-021-91897-7","volume":"11","author":"M Oshi","year":"2021","unstructured":"Oshi M, Tokumaru Y, Angarita FA, Lee L, Yan L, Matsuyama R, et al. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. Sci Rep. 2021;11(1):12541.","journal-title":"Sci Rep"},{"issue":"12","key":"3500_CR198","doi-asserted-by":"publisher","first-page":"348","DOI":"10.31083\/j.fbl2812348","volume":"28","author":"M He","year":"2023","unstructured":"He M, Xu S, Yan F, Ruan J, Zhang X. Fatty acid metabolism: A new perspective in breast cancer precision therapy. Front Biosci (Landmark Ed). 2023;28(12):348.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"20","key":"3500_CR199","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","volume":"27","author":"S Jiralerspong","year":"2009","unstructured":"Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297\u2013302.","journal-title":"J Clin Oncol"},{"key":"3500_CR200","doi-asserted-by":"crossref","unstructured":"Cejuela M, Martin-Castillo B, Menendez JA, Pernas S. Metformin and breast cancer: where are we now?? Int J Mol Sci. 2022;23(5):2705.","DOI":"10.3390\/ijms23052705"},{"issue":"124","key":"3500_CR201","doi-asserted-by":"publisher","first-page":"124ra27","DOI":"10.1126\/scitranslmed.3003293","volume":"4","author":"C Lee","year":"2012","unstructured":"Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4(124):124ra27.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3500_CR202","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1038\/s41467-020-16138-3","volume":"11","author":"S de Groot","year":"2020","unstructured":"de Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG, et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun. 2020;11(1):3083.","journal-title":"Nat Commun"},{"issue":"1","key":"3500_CR203","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ijc.34701","volume":"154","author":"F Ligorio","year":"2024","unstructured":"Ligorio F, Lobefaro R, Fuca G, Provenzano L, Zanenga L, Nasca V, et al. Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial. Int J Cancer. 2024;154(1):114\u201323.","journal-title":"Int J Cancer"},{"issue":"2","key":"3500_CR204","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cmet.2024.11.004","volume":"37","author":"F Ligorio","year":"2025","unstructured":"Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F, et al. Early downmodulation of tumor Glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients. Cell Metab. 2025;37(2):330\u201344. e7.","journal-title":"Cell Metab"},{"issue":"2","key":"3500_CR205","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cmet.2024.12.015","volume":"37","author":"MD Goncalves","year":"2025","unstructured":"Goncalves MD, Iyengar NM. Fueling metabolic disruption via FMD to boost chemotherapy in TNBC. Cell Metab. 2025;37(2):305\u20136.","journal-title":"Cell Metab"},{"key":"3500_CR206","doi-asserted-by":"publisher","first-page":"899335","DOI":"10.3389\/fonc.2022.899335","volume":"12","author":"Y Lu","year":"2022","unstructured":"Lu Y, Wang P, Lan N, Kong F, Abdumijit A, Tu S, et al. Metabolic syndrome predicts response to neoadjuvant chemotherapy in breast cancer. Front Oncol. 2022;12:899335.","journal-title":"Front Oncol"},{"key":"3500_CR207","doi-asserted-by":"publisher","first-page":"1080054","DOI":"10.3389\/fonc.2022.1080054","volume":"12","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Zhang Y, Li Y, Jiang C, Wu Y, Shang L, et al. Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study. Front Oncol. 2022;12:1080054.","journal-title":"Front Oncol"},{"issue":"4","key":"3500_CR208","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s43018-024-00725-0","volume":"5","author":"YZ Jiang","year":"2024","unstructured":"Jiang YZ, Ma D, Jin X, Xiao Y, Yu Y, Shi J, et al. Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nat Cancer. 2024;5(4):673\u201390.","journal-title":"Nat Cancer"},{"issue":"10","key":"3500_CR209","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.tem.2021.07.001","volume":"32","author":"Y Liu","year":"2021","unstructured":"Liu Y, Zhou Q, Song S, Tang S. Integrating metabolic reprogramming and metabolic imaging to predict breast cancer therapeutic responses. Trends Endocrinol Metab. 2021;32(10):762\u201375.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"3500_CR210","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","volume":"33","author":"Y Gong","year":"2021","unstructured":"Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, et al. Metabolic-Pathway-Based subtyping of Triple-Negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021;33(1):51\u2013e649.","journal-title":"Cell Metab"},{"key":"3500_CR211","doi-asserted-by":"crossref","unstructured":"Witt BL, Tollefsbol TO, Molecular. Cellular, and technical aspects of breast cancer cell lines as a foundational tool in cancer research. Life (Basel). 2023;13(12):2311.","DOI":"10.3390\/life13122311"},{"issue":"1","key":"3500_CR212","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/s41467-021-22303-z","volume":"12","author":"D Georgopoulou","year":"2021","unstructured":"Georgopoulou D, Callari M, Rueda OM, Shea A, Martin A, Giovannetti A, et al. Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nat Commun. 2021;12(1):1998.","journal-title":"Nat Commun"},{"issue":"1","key":"3500_CR213","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s42003-020-1042-x","volume":"3","author":"P Savage","year":"2020","unstructured":"Savage P, Pacis A, Kuasne H, Liu L, Lai D, Wan A, et al. Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. Commun Biol. 2020;3(1):310.","journal-title":"Commun Biol"},{"issue":"1","key":"3500_CR214","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13058-024-01794-w","volume":"26","author":"J Lee","year":"2024","unstructured":"Lee J, Lee G, Park HS, Jeong BK, Gong G, Jeong JH, et al. Factors associated with engraftment success of patient-derived xenografts of breast cancer. Breast Cancer Res. 2024;26(1):49.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3500_CR215","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13058-017-0920-8","volume":"19","author":"J Yu","year":"2017","unstructured":"Yu J, Qin B, Moyer AM, Sinnwell JP, Thompson KJ, Copland JA 3, et al. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Res. 2017;19(1):130.","journal-title":"Breast Cancer Res"},{"issue":"11","key":"3500_CR216","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/nm.2454","volume":"17","author":"YS DeRose","year":"2011","unstructured":"DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17(11):1514\u201320.","journal-title":"Nat Med"},{"key":"3500_CR217","doi-asserted-by":"publisher","first-page":"e2300724","DOI":"10.1200\/PO.23.00724","volume":"8","author":"C Vaklavas","year":"2024","unstructured":"Vaklavas C, Matsen CB, Chu Z, Boucher KM, Scherer SD, Pathi S, et al. TOWARDS study: Patient-Derived xenograft engraftment predicts poor survival in patients with newly diagnosed Triple-Negative breast cancer. JCO Precis Oncol. 2024;8:e2300724.","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"3500_CR218","doi-asserted-by":"publisher","first-page":"e0136851","DOI":"10.1371\/journal.pone.0136851","volume":"10","author":"PF McAuliffe","year":"2015","unstructured":"McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, et al. Ability to generate patient-Derived breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes. PLoS ONE. 2015;10(9):e0136851.","journal-title":"PLoS ONE"},{"key":"3500_CR219","doi-asserted-by":"crossref","unstructured":"Goetz MP, Kalari KR, Suman VJ, Moyer AM, Yu J, Visscher DW et al. Tumor sequencing and Patient-Derived xenografts in the neoadjuvant treatment of breast cancer. J Natl Cancer Inst. 2017;109(7):djw306.","DOI":"10.1093\/jnci\/djw306"},{"issue":"17","key":"3500_CR220","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1158\/1078-0432.CCR-21-0641","volume":"27","author":"JC Boughey","year":"2021","unstructured":"Boughey JC, Suman VJ, Yu J, Santo K, Sinnwell JP, Carter JM, et al. Patient-Derived xenograft engraftment and breast cancer outcomes in a prospective neoadjuvant study (BEAUTY). Clin Cancer Res. 2021;27(17):4696\u20139.","journal-title":"Clin Cancer Res"},{"key":"3500_CR221","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1126\/scitranslmed.aav0936","volume":"11","author":"GV Echeverria","year":"2019","unstructured":"Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci Transl Med. 2019;11:488.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3500_CR222","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41467-020-16199-4","volume":"11","author":"O Saatci","year":"2020","unstructured":"Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, et al. Targeting Lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat Commun. 2020;11(1):2416.","journal-title":"Nat Commun"},{"issue":"1","key":"3500_CR223","doi-asserted-by":"publisher","first-page":"17899","DOI":"10.1038\/s41598-020-74882-4","volume":"10","author":"RT Powell","year":"2020","unstructured":"Powell RT, Redwood A, Liu X, Guo L, Cai S, Zhou X, et al. Pharmacologic profiling of patient-derived xenograft models of primary treatment-naive triple-negative breast cancer. Sci Rep. 2020;10(1):17899.","journal-title":"Sci Rep"},{"issue":"7","key":"3500_CR224","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"Thorel L, Perreard M, Florent R, Divoux J, Coffy S, Vincent A, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med. 2024;56(7):1531\u201351.","journal-title":"Exp Mol Med"},{"key":"3500_CR225","doi-asserted-by":"crossref","unstructured":"Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1\u20132):373386 e10.","DOI":"10.1016\/j.cell.2017.11.010"},{"issue":"1","key":"3500_CR226","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/s41467-020-15548-7","volume":"11","author":"JM Rosenbluth","year":"2020","unstructured":"Rosenbluth JM, Schackmann RCJ, Gray GK, Selfors LM, Li CM, Boedicker M, et al. Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages. Nat Commun. 2020;11(1):1711.","journal-title":"Nat Commun"},{"issue":"8","key":"3500_CR227","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-15-2402","volume":"76","author":"CG Hubert","year":"2016","unstructured":"Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, Prager BC, et al. A Three-Dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res. 2016;76(8):2465\u201377.","journal-title":"Cancer Res"},{"issue":"1","key":"3500_CR228","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/organoids1010008","volume":"1","author":"E Richiardone","year":"2022","unstructured":"Richiardone E, Van den Bossche V, Corbet C. Metabolic studies in organoids: current applications, opportunities and challenges. Organoids. 2022;1(1):85\u2013105.","journal-title":"Organoids"},{"issue":"6","key":"3500_CR229","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.neo.2019.04.004","volume":"21","author":"JT Sharick","year":"2019","unstructured":"Sharick JT, Jeffery JJ, Karim MR, Walsh CM, Esbona K, Cook RS, et al. Cellular metabolic heterogeneity in vivo is recapitulated in tumor organoids. Neoplasia. 2019;21(6):615\u201326.","journal-title":"Neoplasia"},{"key":"3500_CR230","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fonc.2020.00553","volume":"10","author":"JT Sharick","year":"2020","unstructured":"Sharick JT, Walsh CM, Sprackling CM, Pasch CA, Pham DL, Esbona K, et al. Metabolic heterogeneity in patient Tumor-Derived organoids by primary site and drug treatment. Front Oncol. 2020;10:553.","journal-title":"Front Oncol"},{"issue":"18","key":"3500_CR231","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1158\/0008-5472.CAN-14-0663","volume":"74","author":"AJ Walsh","year":"2014","unstructured":"Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, et al. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res. 2014;74(18):5184\u201394.","journal-title":"Cancer Res"},{"issue":"2","key":"3500_CR232","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","volume":"3","author":"KP Guillen","year":"2022","unstructured":"Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022;3(2):232\u201350.","journal-title":"Nat Cancer"},{"issue":"7","key":"3500_CR233","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/s41416-024-02595-w","volume":"130","author":"HS Ye","year":"2024","unstructured":"Ye HS, Zhou D, Li H, Lv J, Huang HQ, She JJ, et al. Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy. Br J Cancer. 2024;130(7):1109\u201318.","journal-title":"Br J Cancer"},{"issue":"1","key":"3500_CR234","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1080\/07853890.2022.2122550","volume":"54","author":"D Shu","year":"2022","unstructured":"Shu D, Shen M, Li K, Han X, Li H, Tan Z, et al. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy. Ann Med. 2022;54(1):2581\u201397.","journal-title":"Ann Med"},{"issue":"1","key":"3500_CR235","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12935-024-03375-5","volume":"24","author":"S Mazzucchelli","year":"2024","unstructured":"Mazzucchelli S, Signati L, Messa L, Franceschini A, Bonizzi A, Castagnoli L, et al. Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution. Cancer Cell Int. 2024;24(1):220.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"3500_CR236","doi-asserted-by":"publisher","first-page":"e10141","DOI":"10.15252\/msb.202010141","volume":"17","author":"K Radic Shechter","year":"2021","unstructured":"Radic Shechter K, Kafkia E, Zirngibl K, Gawrzak S, Alladin A, Machado D, et al. Metabolic memory underlying minimal residual disease in breast cancer. Mol Syst Biol. 2021;17(10):e10141.","journal-title":"Mol Syst Biol"},{"issue":"1","key":"3500_CR237","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41420-025-02505-w","volume":"11","author":"Q Wang","year":"2025","unstructured":"Wang Q, Yuan F, Zuo X, Li M. Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments. Cell Death Discov. 2025;11(1):222.","journal-title":"Cell Death Discov"},{"issue":"6","key":"3500_CR238","doi-asserted-by":"publisher","first-page":"100792","DOI":"10.1016\/j.crmeth.2024.100792","volume":"4","author":"A Raffo-Romero","year":"2024","unstructured":"Raffo-Romero A, Ziane-Chaouche L, Salome-Desnoulez S, Hajjaji N, Fournier I, Salzet M, et al. A co-culture system of macrophages with breast cancer tumoroids to study cell interactions and therapeutic responses. Cell Rep Methods. 2024;4(6):100792.","journal-title":"Cell Rep Methods"},{"issue":"8","key":"3500_CR239","doi-asserted-by":"publisher","first-page":"105021","DOI":"10.1016\/j.jbc.2023.105021","volume":"299","author":"JM Hogstrom","year":"2023","unstructured":"Hogstrom JM, Cruz KA, Selfors LM, Ward MN, Mehta TS, Kanarek N, et al. Simultaneous isolation of hormone receptor-positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms. J Biol Chem. 2023;299(8):105021.","journal-title":"J Biol Chem"},{"key":"3500_CR240","doi-asserted-by":"publisher","unstructured":"Nguyen HP, An K, Ito Y, Kharbikar BN, Sheng R, Paredes B et al. Implantation of engineered adipocytes suppresses tumor progression in cancer models. Nat Biotechnol. 2025:1\u20137. https:\/\/doi.org\/10.1038\/s41587-024-02551-2","DOI":"10.1038\/s41587-024-02551-2"},{"issue":"21","key":"3500_CR241","doi-asserted-by":"publisher","first-page":"e2102418","DOI":"10.1002\/advs.202102418","volume":"8","author":"G Fang","year":"2021","unstructured":"Fang G, Lu H, Rodriguez de la Fuente L, Law AMK, Lin G, Jin D, et al. Mammary tumor organoid culture in Non-Adhesive alginate for luminal mechanics and High-Throughput drug screening. Adv Sci (Weinh). 2021;8(21):e2102418.","journal-title":"Adv Sci (Weinh)"},{"issue":"44","key":"3500_CR242","doi-asserted-by":"publisher","first-page":"e2410547","DOI":"10.1002\/adma.202410547","volume":"36","author":"S Kheiri","year":"2024","unstructured":"Kheiri S, Yakavets I, Cruickshank J, Ahmadi F, Berman HK, Cescon DW, et al. Microfluidic platform for generating and releasing Patient-Derived cancer organoids with diverse shapes: insight into Shape-Dependent tumor growth. Adv Mater. 2024;36(44):e2410547.","journal-title":"Adv Mater"},{"issue":"2","key":"3500_CR243","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1039\/D1LC00689D","volume":"22","author":"J Dornhof","year":"2022","unstructured":"Dornhof J, Kieninger J, Muralidharan H, Maurer J, Urban GA, Weltin A. Microfluidic organ-on-chip system for multi-analyte monitoring of metabolites in 3D cell cultures. Lab Chip. 2022;22(2):225\u201339.","journal-title":"Lab Chip"},{"issue":"3","key":"3500_CR244","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/0008-5472.CAN-21-0799","volume":"82","author":"S Chakrabarty","year":"2022","unstructured":"Chakrabarty S, Quiros-Solano WF, Kuijten MMP, Haspels B, Mallya S, Lo CSY, et al. A microfluidic Cancer-on-Chip platform predicts drug response using organotypic tumor slice culture. Cancer Res. 2022;82(3):510\u201320.","journal-title":"Cancer Res"},{"issue":"26","key":"3500_CR245","doi-asserted-by":"publisher","first-page":"e2300905","DOI":"10.1002\/adhm.202300905","volume":"12","author":"W Shi","year":"2023","unstructured":"Shi W, Mirza S, Kuss M, Liu B, Hartin A, Wan S, et al. Embedded Bioprinting of breast tumor cells and organoids using Low-Concentration Collagen-Based Bioinks. Adv Healthc Mater. 2023;12(26):e2300905.","journal-title":"Adv Healthc Mater"},{"issue":"21","key":"3500_CR246","doi-asserted-by":"publisher","first-page":"27151","DOI":"10.1021\/acsami.4c04135","volume":"16","author":"P Gonzalez-Callejo","year":"2024","unstructured":"Gonzalez-Callejo P, Garcia-Astrain C, Herrero-Ruiz A, Henriksen-Lacey M, Seras-Franzoso J, Abasolo I, et al. 3D bioprinted Tumor-Stroma models of Triple-Negative breast cancer stem cells for preclinical targeted therapy evaluation. ACS Appl Mater Interfaces. 2024;16(21):27151\u201363.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"3500_CR247","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1038\/s41467-023-38832-8","volume":"14","author":"PJ Tebon","year":"2023","unstructured":"Tebon PJ, Wang B, Markowitz AL, Davarifar A, Tsai BL, Krawczuk P, et al. Drug screening at single-organoid resolution via Bioprinting and interferometry. Nat Commun. 2023;14(1):3168.","journal-title":"Nat Commun"},{"key":"3500_CR248","doi-asserted-by":"publisher","first-page":"153473541984804","DOI":"10.1177\/1534735419848047","volume":"18","author":"P Lasso","year":"2019","unstructured":"Lasso P, Llano Murcia M, Sandoval TA, Uruena C, Barreto A, Fiorentino S. Breast tumor cells highly resistant to drugs are controlled only by the immune response induced in an immunocompetent mouse model. Integr Cancer Ther. 2019;18:1534735419848047.","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"3500_CR249","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12282-024-01543-z","volume":"31","author":"H Zheng","year":"2024","unstructured":"Zheng H, Wu L, Chen J, Na N, Lou G. Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models. Breast Cancer. 2024;31(3):371\u201381.","journal-title":"Breast Cancer"},{"issue":"7","key":"3500_CR250","doi-asserted-by":"publisher","first-page":"1596005","DOI":"10.1080\/2162402X.2019.1596005","volume":"8","author":"A Burlion","year":"2019","unstructured":"Burlion A, Ramos RN, Kc P, Sendeyo K, Corneau A, Menetrier-Caux C, et al. A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system. Oncoimmunology. 2019;8(7):1596005.","journal-title":"Oncoimmunology"},{"issue":"2","key":"3500_CR251","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"3500_CR252","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3389\/fonc.2020.00428","volume":"10","author":"X Sun","year":"2020","unstructured":"Sun X, Wang M, Wang M, Yu X, Guo J, Sun T, et al. Metabolic reprogramming in Triple-Negative breast cancer. Front Oncol. 2020;10:428.","journal-title":"Front Oncol"},{"issue":"3","key":"3500_CR253","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3343\/alm.2024.0482","volume":"45","author":"A Lee","year":"2025","unstructured":"Lee A, Lam CW. Application of metabolic biomarkers in breast cancer: A literature review. Ann Lab Med. 2025;45(3):229\u201346.","journal-title":"Ann Lab Med"},{"key":"3500_CR254","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2350-13-45","volume":"13","author":"TA Seredina","year":"2012","unstructured":"Seredina TA, Goreva OB, Talaban VO, Grishanova AY, Lyakhovich VV. Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. BMC Med Genet. 2012;13:45.","journal-title":"BMC Med Genet"},{"issue":"5","key":"3500_CR255","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/sj.tpj.6500434","volume":"7","author":"S Marsh","year":"2007","unstructured":"Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, et al. Pharmacogenetic analysis of Paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007;7(5):362\u20135.","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"3500_CR256","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/sj.bjc.6605587","volume":"102","author":"J Bray","year":"2010","unstructured":"Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010;102(6):1003\u20139.","journal-title":"Br J Cancer"},{"key":"3500_CR257","doi-asserted-by":"publisher","first-page":"100645","DOI":"10.1016\/j.drup.2019.100645","volume":"46","author":"YG Assaraf","year":"2019","unstructured":"Assaraf YG, Brozovic A, Goncalves AC, Jurkovicova D, Line A, Machuqueiro M, et al. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat. 2019;46:100645.","journal-title":"Drug Resist Updat"},{"issue":"8044","key":"3500_CR258","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41586-024-08276-1","volume":"637","author":"L Bornes","year":"2025","unstructured":"Bornes L, van Winden LJ, Geurts VCM, de Bruijn B, Azarang L, Lanfermeijer M, et al. The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy. Nature. 2025;637(8044):195\u2013204.","journal-title":"Nature"},{"issue":"1","key":"3500_CR259","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41392-023-01380-0","volume":"8","author":"F Danzi","year":"2023","unstructured":"Danzi F, Pacchiana R, Mafficini A, Scupoli MT, Scarpa A, Donadelli M, et al. To metabolomics and beyond: a technological portfolio to investigate cancer metabolism. Signal Transduct Target Ther. 2023;8(1):137.","journal-title":"Signal Transduct Target Ther"},{"key":"3500_CR260","doi-asserted-by":"crossref","unstructured":"Cardoso MR, Silva AAR, Talarico MCR, Sanches PHG, Sforca ML, Rocco SA et al. Metabolomics by NMR combined with machine learning to predict neoadjuvant chemotherapy response for breast cancer. Cancers (Basel). 2022;14(20):5055.","DOI":"10.3390\/cancers14205055"},{"issue":"1","key":"3500_CR261","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41598-017-01924-9","volume":"7","author":"NI Hadi","year":"2017","unstructured":"Hadi NI, Jamal Q, Iqbal A, Shaikh F, Somroo S, Musharraf SG. Serum metabolomic profiles for breast cancer diagnosis, grading and staging by gas Chromatography-Mass spectrometry. Sci Rep. 2017;7(1):1715.","journal-title":"Sci Rep"},{"issue":"10","key":"3500_CR262","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1021\/acs.jproteome.9b00316","volume":"18","author":"J Debik","year":"2019","unstructured":"Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred O, Borgen E, et al. Assessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patients. J Proteome Res. 2019;18(10):3649\u201360.","journal-title":"J Proteome Res"},{"key":"3500_CR263","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11306-017-1168-0","volume":"13","author":"LR Euceda","year":"2017","unstructured":"Euceda LR, Haukaas TH, Giske\u00f8deg\u00e5rd GF, Vettukattil R, Engel J, Silwal-Pandit L, et al. Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy. Metabolomics. 2017;13:37.","journal-title":"Metabolomics"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03500-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03500-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03500-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:28:48Z","timestamp":1757377728000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03500-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":263,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3500"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03500-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FP.D. reports a relationship with Foundation Against Cancer that includes: funding grants. C.vM. reports a relationship with Belgian Society of Medical Oncology vzw that includes: board membership. C.vM. reports a relationship with Eli Lilly and Company, Novartis, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Menarini Laboratories, that includes: consulting or advisory. C.vM. reports a relationship with AstraZeneca Pharmaceuticals LP, Merck & Co Inc, and Menarini Laboratories that includes: speaking and lecture fees. C.vM. reports a relationship with DigiCore and Gilead Sciences Inc that includes: funding grants. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"234"}}